{"organizations": [], "uuid": "4b1f22b8a19918bae779b574eabad7b1024d966a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-lilly-reports-additional-top-line/brief-lilly-reports-additional-top-line-results-from-cyramza-phase-3-range-study-idUSFWN1RX0UJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Lilly Reports Additional Top-Line Results From Cyramza Phase 3 Range Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-20T21:57:00.000+03:00", "replies_count": 0, "uuid": "4b1f22b8a19918bae779b574eabad7b1024d966a"}, "author": "", "url": "https://www.reuters.com/article/brief-lilly-reports-additional-top-line/brief-lilly-reports-additional-top-line-results-from-cyramza-phase-3-range-study-idUSFWN1RX0UJ", "ord_in_thread": 0, "title": "BRIEF-Lilly Reports Additional Top-Line Results From Cyramza Phase 3 Range Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "eli lilly", "sentiment": "none"}, {"name": "cyramza phase 3 range study reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 20, 2018 / 6:58 PM / in an hour BRIEF-Lilly Reports Additional Top-Line Results From Cyramza Phase 3 Range Study Reuters Staff 1 Min Read \nApril 20 (Reuters) - Eli Lilly and Co: \n* LILLY REPORTS ADDITIONAL TOP-LINE RESULTS FROM CYRAMZAÂ® (RAMUCIRUMAB) PHASE 3 RANGE STUDY IN ADVANCED OR METASTATIC UROTHELIAL CANCER \n* SAYS SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL PREVIOUSLY REPORTED * SAYS IMPROVEMENT IN OBJECTIVE RESPONSE RATE OBSERVED \n* SAYS POSITIVE TREND IN OVERALL SURVIVAL DID NOT REACH STATISTICAL SIGNIFICANCE * SAYS NO NEW SAFETY SIGNALS WERE OBSERVED \n* SAYS POSITIVE TREND WAS SEEN IN SECONDARY ENDPOINT OF OVERALL SURVIVAL WHICH DID NOT REACH STATISTICAL SIGNIFICANCE \n* SAYS SAFETY PROFILE OBSERVED IN RANGE STUDY CONSISTENT WITH WHAT WAS SEEN PREVIOUSLY IN TRIAL & HAS BEEN PREVIOUSLY OBSERVED FOR CYRAMZA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-20T21:57:00.000+03:00", "crawled": "2018-04-20T22:50:43.004+03:00", "highlightTitle": ""}